Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Aug 18, 2026, 10:38 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 30, 2026, 3:41 PMAvi Kapoor
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Read original at benzinga
ACTU BE KYMR SFM SKHY
BenzingaJul 30, 2026, 12:21 PMBenzinga Newsdesk
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
Read original at benzinga
ACTU
SEC EDGARJul 17, 2026, 8:30 PMSEC EDGAR
8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)
Filed: 2026-07-17 AccNo: 0001683168-26-005616 Size: 205 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Read original at edgar
ACTU